HypoxiaIHOBMPBRNCT06264193
The Impact of Hypoxia on the Biochemical and Morphological Parameters of Blood in Rowers.
A study testing Normobaric hypoxia (LHTL) in people with Hypoxia and Normobaric Hypoxia, run by Poznan University of Physical Education.
Trial summary
The response to hypoxia is very individual and depending on many aspects, such as the type of training, duration, intensity, or hypoxic stimulus, hypoxia affects the athlete in various ways. Read more about this study
- Who is it for?
- Ages 18 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Hypoxia, Normobaric Hypoxia
- What is being tested?
- Normobaric hypoxia (LHTL)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- No sites listed yet
- Study dates
- 30 Nov 2014to 21 Dec 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male national-team rowers aged ≥18 years.
- Regular participation in rowing training.
- Participation in the training camp.
Who cannot join
- Exposure to hypoxic conditions or altitude above 1500 m within 1 month before the study.
- Medical contraindications or adverse symptoms associated with hypoxic exposure.
- Injury or health condition preventing participation in the training program.
About this study
Official title: The Effects of Live High-train Low on EPO, VEGF, and Hematological Variables in Elite Rowers
The response to hypoxia is very individual and depending on many aspects, such as the type of training, duration, intensity, or hypoxic stimulus, hypoxia affects the athlete in various ways. This multi-stage study investigated hematological and physiological responses to normobaric Live High-Train Low (LHTL) exposure in elite male rowers from the Polish national rowing team. Stage I evaluated responses during an 18-day LHTL intervention, whereas Stage II evaluated responses during a 14-day LHTL intervention and extended the assessment to 42 days after return to normoxia. The study focused particularly on hematological variables, erythropoietin (EPO), vascular endothelial growth factor (VEGF), and other physiological and biochemical responses associated with hypoxic exposure.
Read the detailed description
I stage. The Polish national rowing team athletes, 13 males, were randomly divided into two groups:
- The hypoxic group (H) included 8 rowers participating in sports training and the LHTL intervention, with progressive normobaric hypoxic exposure corresponding to simulated altitudes of 2000, 2500, and 3000 m.
- The control group (C) consisted of 5 rowers participating only in sports training and living in normoxic rooms at the same sports camp. Rowers were observed during the preparatory period. The hypoxic group lived and slept in hypoxic rooms for at least 8-14 hours per day. During the camp, all rowers followed the same training schedule and diet. All participants' saturation and heart rate were measured daily, morning and evening, throughout the camp period. Venous blood samples were taken four times, at the beginning of the camp (Baseline), after 6 days, after 12 days, and after 18 days of the camp. Body composition parameters such as body mass index, body fat, and free fat mass were estimated using the bioelectrical impedance method of a Tanita BC 418 analyzer (Japan). Data analysis was performed using Statistica. The response to hypoxia is very individual. Depending on many factors, such as training type, duration, intensity, or hypoxic stimulus, hypoxia affects athletes in various ways. The results of this study have shown that the blood parameters did not increase significantly in the hypoxic group compared to the control group. However, reticulocytes, immature red blood cells, have shown significant differences after 18-d LHTL between groups. Further research should be carried out to investigate an optimal hypoxic dose and time, which will raise EPO, VEGF, and morphology variables.
II stage. Fourteen elite male rowers from the Polish national rowing team participated in the second stage and were randomly allocated to the LHTL group (n = 8) or the normoxic control group (n = 6). Both groups followed the same standardized training program. The LHTL intervention lasted 14 consecutive days and involved progressive normobaric hypoxic exposure corresponding to 2000-3000 m for approximately 14-16 h/day, while all training sessions were performed under normoxic conditions. Blood samples were collected at baseline, after 7 and 14 days of the intervention, and 8, 14, and 42 days after completion. Hematological variables, EPO, VEGF, iron-related indices, CK activity, and lipid-profile variables were assessed, while SpO₂ and resting HR were monitored throughout the intervention.
- Conditions
- Hypoxia, Normobaric Hypoxia
- Being tested
- Normobaric hypoxia (LHTL)
- Keywords
- hypoxia, rowers, exercise, EPO, athletes, LH-TL, hematological adaptation, elite athletes
- Medical subject headings
- Hypoxia, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Normobaric hypoxia (LHTL)Other
Participants lived in normobaric hypoxic rooms for 14-16 h per day while completing their regular training under normoxic conditions. The simulated altitude was progressively increased during the intervention.
| Study group | Role | What they receive |
|---|---|---|
| LHTL | Experimental | Participants assigned to the LHTL group underwent their regular sports training while living in normobaric hypoxic rooms. Receives: Other: Normobaric hypoxia (LHTL) |
| Control group | No intervention | Participants assigned to the control group completed the same sports training as the LHTL group while living in normoxic conditions at the same training camp. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Erythropoietin (EPO) mlU/ml
immunoenzymatic assay methods using diagnostic kits
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Vascular endothelial growth factor (VEGF) mlU/ml
immunoenzymatic assay methods using diagnostic kits
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Secondary outcomes (9)
Creatine kinase (CK) ng/ml
was determined using spectrophotometer analysis and diagnostic kits
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Hs C-Reactive Protein (hsCRP) mg/L
was determined by immunoenzymatic assay methods using diagnostic kits
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention.
Hemoglobin (Hb)g/dL
A professional accredited laboratory company determined the Hb level (Poland, ISO 9001:2008).
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Hematocrit (Htc)%
A professional accredited laboratory company determined the Htc level (Poland, ISO 9001:2008).
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Red blood cells (RBC)mln/mm3
A professional accredited laboratory company determined the RBC level (Poland, ISO 9001:2008).
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
White blood cells (WBC)10 3/µL
A professional accredited laboratory company determined the WBC level (Poland, ISO 9001:2008).
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Reticulocytes (Ret)‰
A professional accredited laboratory company determined the Ret level (Poland, ISO 9001:2008).
Measured: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Peripheral oxygen saturation (SpO₂) (%)
Peripheral oxygen saturation (SpO₂) was measured non-invasively using a pulse oximeter (Tech-Med, ISO 13485). Measurements were performed twice daily, in the morning and evening, throughout each sports camp in both study groups.
Measured: Stage 1: daily from Day 1 through Day 18 of the intervention, in the morning after waking and in the evening before bedtime; Stage 2: daily from Day 1 through Day 14 of the intervention, in the morning after waking and in the evening before bedtime.
Heart rate (HR) (beats/min)
Heart rate (HR) was measured using a pulse oximeter (Tech-Med, ISO 13485). Measurements were performed twice daily, in the morning and evening, throughout each sports camp in both study groups.
Measured: Stage 1: daily from Day 1 through Day 18 of the intervention; Stage 2: daily from Day 1 through Day 14 of the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Feb 2024
- Study start30 Nov 2014
- Primary completion21 Dec 2015
- Study completion21 Dec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for HypoxiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were assigned to two parallel groups: an LHTL group, which completed the same sports training while living in normobaric hypoxic conditions, and a control group, which completed the same training while living in normoxic conditions. The hypoxic exposure protocol differed between Stage I and Stage II as described in the study protocol.
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Poznan University of Physical Education
- Sponsor type
- University, hospital or other
- Collaborators
- The Polish Rowing Association, Warsaw, Poland.
- Responsible party
- Sponsor
- Investigators
- Anna Kasperska, Principal investigator, Poznań University of Physical Education, Faculty of Sport Sciences in Gorzów Wielkopolski, Poland;
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06264193
- Sponsor's protocol ID
- Rowers LH-TL
- Acronym
- IHOBMPBR
- Status last verified
- Sep 2026
- First submitted
- 10 Jan 2024
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to participant confidentiality and data protection considerations.
Publications
Kasperska A, Zembron-Lacny A. The effect of intermittent hypoxic exposure on erythropoietic response and hematological variables in elite athletes. Physiol Res. 2020 Apr 30;69(2):283-290. doi: 10.33549/physiolres.934316. Epub 2020 Mar 23.
PubMed 32199016Wilber RL. Application of altitude/hypoxic training by elite athletes. Med Sci Sports Exerc. 2007 Sep;39(9):1610-24. doi: 10.1249/mss.0b013e3180de49e6.
PubMed 17805095Czuba M, Fidos-Czuba O, Ploszczyca K, Zajac A, Langfort J. Comparison of the effect of intermittent hypoxic training vs. the live high, train low strategy on aerobic capacity and sports performance in cyclists in normoxia. Biol Sport. 2018 Mar;35(1):39-48. doi: 10.5114/biolsport.2018.70750. Epub 2017 Oct 11.
PubMed 30237660Ploszczyca K, Langfort J, Czuba M. The Effects of Altitude Training on Erythropoietic Response and Hematological Variables in Adult Athletes: A Narrative Review. Front Physiol. 2018 Apr 11;9:375. doi: 10.3389/fphys.2018.00375. eCollection 2018.
PubMed 29695978Kasperska A, Dziewiecka H, Jankowski W, Mikulski T, Czerniec I, Skarpanska-Stejnborn A, Ostapiuk-Karolczuk J. Hematological, inflammatory, and hypoxia-responsive adaptations to 18-day normobaric live high-train low training in elite rowers. Front Physiol. 2026 May 13;17:1834329. doi: 10.3389/fphys.2026.1834329. eCollection 2026.
PubMed 42222289
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Live High-train Low on EPO, VEGF, and Hematological Variables in Elite Rowers
- ClinicalTrials.gov ID
- NCT06264193
- Acronym / sponsor ID
- IHOBMPBR / Rowers LH-TL
- Conditions
- Hypoxia, Normobaric Hypoxia
- Keywords
- hypoxia, rowers, exercise, EPO, athletes, LH-TL, hematological adaptation, elite athletes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Poznan University of Physical EducationUniversity, hospital or other
- Collaborators
- The Polish Rowing Association, Warsaw, Poland.
- Study start
- 30 Nov 2014 (actual)
- Primary completion
- 21 Dec 2015 (actual)
- Study completion
- 21 Dec 2015 (actual)
- First posted
- 16 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The response to hypoxia is very individual and depending on many aspects, such as the type of training, duration, intensity, or hypoxic stimulus, hypoxia affects the athlete in various ways. This multi-stage study investigated hematological and physiological responses to normobaric Live High-Train Low (LHTL) exposure in elite male rowers from the Polish national rowing team. Stage I evaluated responses during an 18-day LHTL intervention, whereas Stage II evaluated responses during a 14-day LHTL intervention and extended the assessment to 42 days after return to normoxia. The study focused particularly on hematological variables, erythropoietin (EPO), vascular endothelial growth factor (VEGF), and other physiological and biochemical responses associated with hypoxic exposure.
Detailed description
I stage. The Polish national rowing team athletes, 13 males, were randomly divided into two groups:
- The hypoxic group (H) included 8 rowers participating in sports training and the LHTL intervention, with progressive normobaric hypoxic exposure corresponding to simulated altitudes of 2000, 2500, and 3000 m.
- The control group (C) consisted of 5 rowers participating only in sports training and living in normoxic rooms at the same sports camp. Rowers were observed during the preparatory period. The hypoxic group lived and slept in hypoxic rooms for at least 8-14 hours per day. During the camp, all rowers followed the same training schedule and diet. All participants' saturation and heart rate were measured daily, morning and evening, throughout the camp period. Venous blood samples were taken four times, at the beginning of the camp (Baseline), after 6 days, after 12 days, and after 18 days of the camp. Body composition parameters such as body mass index, body fat, and free fat mass were estimated using the bioelectrical impedance method of a Tanita BC 418 analyzer (Japan). Data analysis was performed using Statistica. The response to hypoxia is very individual. Depending on many factors, such as training type, duration, intensity, or hypoxic stimulus, hypoxia affects athletes in various ways. The results of this study have shown that the blood parameters did not increase significantly in the hypoxic group compared to the control group. However, reticulocytes, immature red blood cells, have shown significant differences after 18-d LHTL between groups. Further research should be carried out to investigate an optimal hypoxic dose and time, which will raise EPO, VEGF, and morphology variables.
II stage. Fourteen elite male rowers from the Polish national rowing team participated in the second stage and were randomly allocated to the LHTL group (n = 8) or the normoxic control group (n = 6). Both groups followed the same standardized training program. The LHTL intervention lasted 14 consecutive days and involved progressive normobaric hypoxic exposure corresponding to 2000-3000 m for approximately 14-16 h/day, while all training sessions were performed under normoxic conditions. Blood samples were collected at baseline, after 7 and 14 days of the intervention, and 8, 14, and 42 days after completion. Hematological variables, EPO, VEGF, iron-related indices, CK activity, and lipid-profile variables were assessed, while SpO₂ and resting HR were monitored throughout the intervention.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants were assigned to two parallel groups: an LHTL group, which completed the same sports training while living in normobaric hypoxic conditions, and a control group, which completed the same training while living in normoxic conditions. The hypoxic exposure protocol differed between Stage I and Stage II as described in the study protocol.
| Arm | Type | Receives |
|---|---|---|
| LHTL | Experimental | Other: Normobaric hypoxia (LHTL)Participants assigned to the LHTL group underwent their regular sports training while living in normobaric hypoxic rooms. |
| Control group | No intervention | –Participants assigned to the control group completed the same sports training as the LHTL group while living in normoxic conditions at the same training camp. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Male national-team rowers aged ≥18 years.
- Regular participation in rowing training.
- Participation in the training camp.
Key exclusion criteria (3 listed)
- Exposure to hypoxic conditions or altitude above 1500 m within 1 month before the study.
- Medical contraindications or adverse symptoms associated with hypoxic exposure.
- Injury or health condition preventing participation in the training program.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Normobaric hypoxia (LHTL)Participants lived in normobaric hypoxic rooms for 14-16 h per day while completing their regular training under normoxic conditions. The simulated altitude was progressively increased during the intervention. | Other | LHTL |
Primary outcome
Erythropoietin (EPO) mlU/ml
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
immunoenzymatic assay methods using diagnostic kits
Vascular endothelial growth factor (VEGF) mlU/ml
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
immunoenzymatic assay methods using diagnostic kits
9 secondary outcomes
Creatine kinase (CK) ng/ml
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Hs C-Reactive Protein (hsCRP) mg/L
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention.
Hemoglobin (Hb)g/dL
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Hematocrit (Htc)%
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Red blood cells (RBC)mln/mm3
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
White blood cells (WBC)10 3/µL
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Reticulocytes (Ret)‰
Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.
Peripheral oxygen saturation (SpO₂) (%)
Time frame: Stage 1: daily from Day 1 through Day 18 of the intervention, in the morning after waking and in the evening before bedtime; Stage 2: daily from Day 1 through Day 14 of the intervention, in the morning after waking and in the evening before bedtime.
Heart rate (HR) (beats/min)
Time frame: Stage 1: daily from Day 1 through Day 18 of the intervention; Stage 2: daily from Day 1 through Day 14 of the intervention.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- Background: PubMed 32199016Kasperska A, Zembron-Lacny A. The effect of intermittent hypoxic exposure on erythropoietic response and hematological variables in elite athletes. Physiol Res. 2020 Apr 30;69(2):283-290. doi: 10.33549/physiolres.934316. Epub 2020 Mar 23.
- Background: PubMed 17805095Wilber RL. Application of altitude/hypoxic training by elite athletes. Med Sci Sports Exerc. 2007 Sep;39(9):1610-24. doi: 10.1249/mss.0b013e3180de49e6.
- Results publication: PubMed 30237660Czuba M, Fidos-Czuba O, Ploszczyca K, Zajac A, Langfort J. Comparison of the effect of intermittent hypoxic training vs. the live high, train low strategy on aerobic capacity and sports performance in cyclists in normoxia. Biol Sport. 2018 Mar;35(1):39-48. doi: 10.5114/biolsport.2018.70750. Epub 2017 Oct 11.
- Results publication: PubMed 29695978Ploszczyca K, Langfort J, Czuba M. The Effects of Altitude Training on Erythropoietic Response and Hematological Variables in Adult Athletes: A Narrative Review. Front Physiol. 2018 Apr 11;9:375. doi: 10.3389/fphys.2018.00375. eCollection 2018.
- Derived from this study: PubMed 42222289Kasperska A, Dziewiecka H, Jankowski W, Mikulski T, Czerniec I, Skarpanska-Stejnborn A, Ostapiuk-Karolczuk J. Hematological, inflammatory, and hypoxia-responsive adaptations to 18-day normobaric live high-train low training in elite rowers. Front Physiol. 2026 May 13;17:1834329. doi: 10.3389/fphys.2026.1834329. eCollection 2026.
- Exercise and Training at Altitudes: Physiological Effects and ProtocolsLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to participant confidentiality and data protection considerations.
Related trials for Hypoxia
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Enrolling by invitation
Extubation Safety Via Microstream EtCO₂ (IPI) Monitoring
Hypoxemia
Not yet recruiting
Acute Intermittent Hypoxia Therapy for Depression
Major Depressive Disorder (MDD)
Active, not recruitingPhase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Carcinoma, Renal Cell
RecruitingObservational study
Comparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study
Respiratory Failure, Hypoxemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anna Kasperska principal investigator
Poznań University of Physical Education, Faculty of Sport Sciences in Gorzów Wielkopolski, Poland;
Questions about this trial
What is this clinical trial studying?
A study testing Normobaric hypoxia (LHTL) in people with Hypoxia and Normobaric Hypoxia, run by Poznan University of Physical Education.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Erythropoietin (EPO) mlU/ml (time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06264193, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.